ContraFect (CFRX) Prices 11.797M Share & Warrants Offering at $4.90/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- BofA raises hyperscaler AI capex outlook to $3.6tn through 2028
After-Hours Movers Stock 05/21: (RAMP) (PANW) (ELF) Higher; (GERN) (CFRX) (DVAX) Lower (more...)
May 21, 2020 6:00 PM EDTToday's After-Hours Stock Movers:
Geron Corporation (Nasdaq: GERN) 17.9% LOWER; announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of its common stock in an underwritten public offering. All of the securities in the proposed offering are to be sold by Geron. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
ContraFect... More
ContraFect (CFRX) Announces Proposed Public Offering of Common Stock and Warrants
May 21, 2020 4:12 PM EDTContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and warrants to purchase additional shares... More
